Tags

Type your tag names separated by a space and hit enter

ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients.
Clin Immunol 2006; 120(3):342-8CI

Abstract

Enhanced cellular immunity following influenza vaccination has been undetectable in kidney transplant recipients so far. Protection from influenza is dependent on cellular and humoral immunity. Aim of the study was to investigate immune responses before and after vaccination with influenza A and B antigens in 65 kidney transplant recipients. A significant increase in proliferative responses was only observed towards influenza B (P < 0.0001) by lymphocyte transformation test. The enzyme-linked immunospot (ELISpot) assay was more sensitive and detected significant, 3- to 5-fold increases (P < 0.0001) in interferon-gamma secretion using influenza A and B antigens. Furthermore, influenza antibody titers increased significantly (P < 0.0001). At month 1 post-vaccination 85% of patients displayed specific cellular, and 95% or 92% humoral immunity against influenza A and B, respectively. Thus, applying the sensitive ELISpot assay, influenza-specific cellular immunity could be detected for the first time in kidney transplant recipients after vaccination.

Authors+Show Affiliations

Institute of Immunology, University Hospital, Virchowstrasse 171, 45122 Essen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16631409

Citation

Lindemann, Monika, et al. "ELISpot Assay as a Sensitive Tool to Detect Cellular Immunity Following Influenza Vaccination in Kidney Transplant Recipients." Clinical Immunology (Orlando, Fla.), vol. 120, no. 3, 2006, pp. 342-8.
Lindemann M, Witzke O, Lütkes P, et al. ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clin Immunol. 2006;120(3):342-8.
Lindemann, M., Witzke, O., Lütkes, P., Fiedler, M., Kreuzfelder, E., Philipp, T., ... Grosse-Wilde, H. (2006). ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clinical Immunology (Orlando, Fla.), 120(3), pp. 342-8.
Lindemann M, et al. ELISpot Assay as a Sensitive Tool to Detect Cellular Immunity Following Influenza Vaccination in Kidney Transplant Recipients. Clin Immunol. 2006;120(3):342-8. PubMed PMID: 16631409.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. AU - Lindemann,Monika, AU - Witzke,Oliver, AU - Lütkes,Peter, AU - Fiedler,Melanie, AU - Kreuzfelder,Ernst, AU - Philipp,Thomas, AU - Roggendorf,Michael, AU - Grosse-Wilde,Hans, Y1 - 2006/04/21/ PY - 2006/01/26/received PY - 2006/03/09/revised PY - 2006/03/09/accepted PY - 2006/4/25/pubmed PY - 2006/9/27/medline PY - 2006/4/25/entrez SP - 342 EP - 8 JF - Clinical immunology (Orlando, Fla.) JO - Clin. Immunol. VL - 120 IS - 3 N2 - Enhanced cellular immunity following influenza vaccination has been undetectable in kidney transplant recipients so far. Protection from influenza is dependent on cellular and humoral immunity. Aim of the study was to investigate immune responses before and after vaccination with influenza A and B antigens in 65 kidney transplant recipients. A significant increase in proliferative responses was only observed towards influenza B (P < 0.0001) by lymphocyte transformation test. The enzyme-linked immunospot (ELISpot) assay was more sensitive and detected significant, 3- to 5-fold increases (P < 0.0001) in interferon-gamma secretion using influenza A and B antigens. Furthermore, influenza antibody titers increased significantly (P < 0.0001). At month 1 post-vaccination 85% of patients displayed specific cellular, and 95% or 92% humoral immunity against influenza A and B, respectively. Thus, applying the sensitive ELISpot assay, influenza-specific cellular immunity could be detected for the first time in kidney transplant recipients after vaccination. SN - 1521-6616 UR - https://www.unboundmedicine.com/medline/citation/16631409/ELISpot_assay_as_a_sensitive_tool_to_detect_cellular_immunity_following_influenza_vaccination_in_kidney_transplant_recipients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1521-6616(06)00087-8 DB - PRIME DP - Unbound Medicine ER -